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Evaluation of the possibility to detect fetal chromosome trisomies 
based on a defined set of single nucleotide polymorphisms for 
non-invasive prenatal testing 
Abstract 
Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal (cffDNA) from 
mother’s blood sample has shown to be an accurate and reliable screening tool. The current 
NIPT protocols are based on targeted or whole genome sequencing, which demand resource-
intensive bioinformatical capacity. The complexity of current NIPT technology is trustworthy 
but the comprehensive adaption of the application is still limited due to the high cost. 
Mother- and fetus-specific genotypes, according to the nature of cell-free DNA (cfDNA) during 
pregnancy, were simulated and used in further analysis. Simulations and theoretical calculations 
demonstrate the characteristic patterns of allelic ratios in case of normal number of 
chromosomes or trisomy where extra chromosome is inherited from mother or father. Here 
described analytical approach managed to identify fetal trisomy by comparing the allelic ratios 
of the risk chromosome with the expected allelic ratios using the t-test and hidden Markov 
model (HMM) analysis. 
An average, 3/4 of all highly polymorphic single nucleotide polymorphisms (SNPs) can be used 
in analysis based on comparison of the allelic ratios. As a result, at least 300 highly polymorphic 
SNPs over risk and reference chromosomes are needed to detect fetal trisomy using t-test alone. 
In addition, the HMM analysis can independently detect fetal trisomy and have the ability to 
distinguish the parental origin of trisomy. 
Based on the simulated data, the existence and the origin of fetal trisomy is theoretically 
detectable using a novel and highly quantitative SNP-based approach that is under development 
by our research group. However, further testing has to be carried out with the real data to 
confirm the theory. 
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Mitte-invasiivse prenataalse skriiningu taustauuring – kas loote 
kromosoomi trisoomiaid on võimalik määrata ühenukleotiidsete 
polümorfismide valimiga? 
Lühikokkuvõte 
Loote mitte-invasiivne prenataalne testimine (NIPT) ema vereproovist on osutunud täpseks ja 
usaldusväärseks skriiningu tööriistaks. Kasutuses olevad NIPT protokollid põhinevad genoomi 
osalisel või täielikul sekveneerimisel, mis nõuab ressursimahukat bioinformaatilist võimekust. 
NIPT tehnoloogiad on küll usaldusväärsed, kuid nende ulatuslik kasutuselevõtt on piiratud 
eelkõige kõrge hinna tõttu. 
Töö käigus simuleeriti ema- ja lootespetsiifilisi genotüübi andmeid, vastavalt rakuvaba DNA 
olemusele raseda veres, kasutati edaspidises analüüsis. Simulatsioonid ja teoreetilised 
kalkulatsioonid näitavad iseloomulikke alleelsete suhteid nii normaalse kui ka ema- või 
isapoolse trisoomiaga loote korral. Loote riskikromosoomide alleelsete suhete võrdlemisel 
oodatud alleelsete suhetega  
Kirjeldatud analüütiline lähenemine põhineb riskikromosoomide alleelsete suhete ja oodatavate 
alleelsete suhete võrdlusel ning võimaldab tuvastada loote trisoomiat. Statistiliseks analüüsiks 
kasutati t-testi ja varjatud Markovi mudelit (HMM). Analüüsiks on võimalik kasutada 
keskmiselt 3/4 kõikidest kõrge polümorfsusega ühenukleotiidsetest polümorfismidest (SNP). 
T-testi korral läheb loote trisoomia tuvastamiseks vaja ligikaudu 300 kõrge polümorfsusega 
SNP-i, mis paikneksid nii riski- kui ka referentskromosoomides. Lisaks võimaldab HMM 
analüüs t-testust sõltumatult detekteerida loote trisoomiat ning selle vanemlikku päritolu. 
Uudset ning kvantitatiivset SNP-põhist lähenemist kasutades on simuleeritud andmete põhjal 
teoreetiliselt võimalik tuvastada loote trisoomia olemasolu ja pärinevust. Laboratoorne 
metoodika on meie uurimisgrupi poolt hetkel väljatöötamisel ja läbinud edukalt esimese 
testfaasi. Lõpliku kindluse saavutamiseks on vaja analüüsi korrata reaalsetel katseandmetel. 
 
Märksõnad 
prenataalne skriining, mitte-invasiivne prenataalne testimine, ühenukleotiidne polümorfism, 
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ABBREVIATIONS 
cfDNA – cell-free DNA 
cffDNA – cell-free fetal DNA 
CPM – confined placental mosaicism 
DANSR™ – Digital Analysis of Selected Regions 
DS – Down syndrome 
FMCR – fetal-to-maternal cell ratio 
FORTE™ – Fetal Fraction Optimized Risk of Trisomy Evaluation 
HMM – hidden Markov model 
MI – meiosis I 
MII – meiosis II 
NATUS™ – Next-generation Aneuploidy Test Using SNPs 
NGS – next generation sequencing 
NIPT – non-invasive prenatal testing 
PMAP – pointwise maximal a posterior 
PZM – post-zygotic (mitotic) 
SNP – single nucleotide polymorphism 
UPD – uniparental disomy 
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INTRODUCTION 
Changes in fetal chromosome copy number constitute a large part of genetic disorders affecting 
more than half of early embryos (Taylor, Gitlin et al. 2014; McCoy, Demko et al. 2015). 
Prenatal screening and diagnostics aim to detect these problems in time, which may be essential 
for the future parents and the child. 
Fetal chromosomal abnormalities can be detected either by invasive diagnostic tests or by non-
invasive screening tests. The latter are considered less harmful for developing fetus, but in terms 
of detection rates are outperformed by invasive tests. Searching for the methods that can provide 
superior accuracy without the cost of safety has driven the field of prenatal genetic testing for 
years.  
Recent developments in non-invasive prenatal testing have shown promising results and it is 
becoming a widely implemented alternative to conventional serum marker based screening. 
Several commercial platforms are currently available for common autosomal and sex 
chromosome aneuploidies detection. Unfortunately, the adaption of NIPT is limited by the high 
cost, which is due to the fact that current NIPT methods mostly use next-generation sequencing 
(NGS). To fulfill the gap in accurate and affordable methods, we evaluated the possibility to 
detect fetal chromosome trisomies using a highly cost-effective SNP-based approached.  
This study covers the main mechanisms that lead to fetal aneuploidy, especially to trisomy, and 
proposes a theoretical way to calculate expected allelic ratios, which can be used to estimate 
fetal trisomy. Using simulated data, that mimics the cfDNA of a pregnant patient's blood, we 
estimate the underlying fetal condition. 
  
The study was supported by Competence Centre on Health Technologies. 
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1 LITERATURE REVIEW 
1.1 Aneuploidy 
The search for the origin of chromosomal aneuploidy became possible due to the cytogenetic 
analyses of human oocytes in early 1970s (Pellestor et al. 2005). Studies have established that 
aneuploidy is the leading known cause of congenital birth defects. At least 10% of all clinically 
diagnosed pregnancies are trisomic or monsomic. It is assumed that many aneuploid 
conceptions are eliminated during the earliest stages of pregnancy (Nagaoka et al. 2012). 
Aneuploidies are mainly caused by the faults made during oocyte development (Nagaoka et al. 
2012). Two main differences between female and male gametogenesis, that have an effect on 
the errors made in meiosis, are timing and number of cells produced from one parent cell 
(Hassold et al. 2007). 
The majority of errors are caused by different non-disjunctional mechanisms. Some errors are 
associated with failure to crossover, others with crossovers that occur too close or too far from 
the centromere. Also there are mechanisms that have nothing to do with recombination, but are 
attributable to abnormalities in other meiotic processes – loss of sister chromatid cohesion or 
defects in spindle assembly/disassembly, which may lead to mosaicism (Hassold et al. 2007; 
Sherman et al. 2006). The main mechanisms of chromosomal missegregation errors that result 
in aneuploidy or mosaicism – non-disjunction and anaphase lag – are described in detail in the 
next chapters. 
 
1.1.1 Non-disjunction 
Chromosomal non-disjunction is a state, where chromosomes in meiosis I (MI) or sister 
chromatids in meiosis II (MII) fail to separate equally into the daughter cells. This results in 
one cell having two chromosomes or chromatids that remained connected and a cell that has 
none (Lamb et al. 2005). 
Up to five different patterns of abnormal meiotic segregation can be distinguished as described 
in Figure 1. One possible mechanism is the achiasmate non-disjunction, in which homologues 
fail to pair and/or recombine and segregate to the same pole due to the absence of chiasma 
(Figure 1B). The second possible mechanism involves premature separation of sister 
chromatids (PSSC), where sister chromatids segregate from a univalent in MI (Figure 1C). 
PSSC may be caused by premature biorientation of sister chromatid centromeres of univalents 
during MI to avoid spindle assembly checkpoint (Kouznetsova et al. 2007). The third 
mechanism is the “true” non-disjunction at MI, which probably originates from the joint 
segregation of a linear bivalent showing a single distal chiasma (Figure 1D). The presence of a 
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proximal chiasma can lead to a premature loss of centromeric cohesion between chromatids 
and their subsequent segregation at random (Rockmill et al. 2006). This has been observed in 
MII oocytes and is called a balanced PSSC (Figure 1E). The true non-disjunction at MII implies 
the segregation of the two sister chromatids to the same pole (Figure 1F). It is thought that this 
happens because of the inability to lose cohesion between centromeres of sister chromatids or 
a bad orientation in the metaphase plate (Templado et al. 2013). 
Studies on human oocytes and sperms have repeatedly shown achiasmate non-disjunction and 
PSSC as the two main mechanisms generating aneuploidy in MI (Fragouli et al. 2011; Uroz & 
Templado 2012). The errors in MII usually result from the failure of sister chromatid separation 
(Hassold & Hunt 2001). Most of the remaining bivalent errors of MI had exchanges occurring 
near the telomeres. In contrast, errors of MII seemed to cluster at the pericentromeric region of 
the chromosome. It is suggested that since susceptibility to non-disjunction is associated with 
the distance between the centromere and the nearest exchange, errors of MII are not 
independent events, as widely believed, but errors of MI resolved in a later stage (Lamb 1997). 
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Figure 1. Meiotic non-disjunction on the example of spermatozoa. (A) Normal chromosome segregation during meiosis. 
(B) Achiasmate non-disjunction involves the random segregation of two homologous chromosomes at MI. (C) Premature 
separation of sister chromatids (PSSC) is caused by the sister chromatids being segregated from one another in MI. (D) “True” 
non-disjunction at MI means that homologues travel to the same pole. (E) Balanced PSSC is characterized by the random 
segregation of two separated sister chromatids at MII. (F) True non-disjunction at MII originates by the joint segregation of 
the sister chromatids that maintain their cohesion. R – recombination. Adjusted from Templado et al., 2013. 
 
1.1.2 Anaphase lag 
Chromosome non-disjunction and anaphase lagging are two different mechanisms that 
contribute to mono- and trisomies. Anaphase lagging is defined as the failure of a single 
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chromosome or chromatid to be incorporated into the nucleus despite the attachment to the 
spindle or caused by the failure to attach to the spindle. This results in a monosomy of the 
chromosome in one cell and a disomy of corresponding chromosome in the other cell (Coonen 
et al. 2004). 
Aside from aneuploidies, anaphase lag can lead to a uniparental disomy (UPD) – a case where 
both copies of a chromosome originate from the same parent. This may occasionally occur 
when a trisomic conceptus loses one extra chromosome to regain normal chromosomal 
constitution by mitotic non-disjunction or anaphase lag. In one third of cases, the remaining 
homologues originate only from one parent (Nicolaidis & Petersen 1998). 
 
1.1.3 Mosaicism 
Another set of whole chromosome aneuploidies affecting embryos, which result from 
chromosome missegregation during the first mitotic cell divisions in cleavage stage, leads to 
mosaicism – a condition in which a person has two or more genetically distinct cell lines that 
originated from a single zygote (Delhanty et al. 1993). 
Confined placental mosaicism (CPM) is a subtype of mosaicism, in which only fetal and 
placental tissues contain differences in chromosome number. CPM serves as a challenge for 
NIPT screening as a source of false positive results, as majority of the cfDNA originates from 
placental tissue (Bayindir et al. 2015). CPM appears in approximately 6% of all pregnancies. 
The prevalence of chromosomal mosaicism in placental tissue in case of an euploid fetus is 
thought to be 1–2% (Taylor et al. 2014). Out of all people with any kind of DS, mosaicism for 
trisomy 21 is estimated to be present in 1.3–5% (Papavassiliou et al. 2015). 
 
1.1.4 Parental origin 
There is a consensus that possibly more than 90% of aneuploidies originate from maternal 
meiotic errors (Robinson et al. 1995; Hassold & Hunt 2001). Several potential causes have been 
proposed for the considerably higher proportion of maternal errors. Most of the examples and 
evidence is based on trisomy 21 as the most frequent and studied autosomal trisomy. These 
include exceptionally long MI during oogenesis, that spans from fetal development up to 
menopause (Hassold et al. 2007), and higher stringency in the elimination of trisomy 21 cells 
during fetal testicular than ovarian development (Iwarsson et al. 2015). Another theory proposes 
an explanation through trisomy 21 mosaicism in fetal ovaries, which means that female 
embryos already have a trisomic cell population in their ovaries (Hultén et al. 2010). 
Only less than 10% aneuploidy is assumed to originate from the paternal line, and therefore 
significantly less studies have been dedicated to the understanding of paternal origin (Hassold 
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& Hunt 2001). Male gametes are continuously produced from male germ cells that are 
mitotically dividing in the sexually mature adult before entering meiosis. Male gametes are 
therefore under much less temporal strain, and sperm production is maintained throughout 
lifetime. Most aneuploidies in male gametes concern the sex chromosomes because during male 
meiosis, XY chromosomes that harbor only a limited region of homology have to pair and 
segregate, in contrary to female meiosis where the XX chromosome pair does not create 
additional challenges (Hassold & Hunt 2001). As in maternal origin, the main mechanism 
causing meiotic segregation errors in human sperm is non-disjunction, followed by anaphase 
lag. Achiasmate non-disjunction and PSSC are found to be main contributors to non-disjunction 
in MI in work on infertile patient and fertile men (Uroz & Templado 2012).  
Despite the unbalance towards maternal contribution, parental origin is found to be 
chromosome-dependent (Table 1). According to the data, trisomies of acrocentric 
chromosomes 13, 15, 21 and 22 originate from maternal MI, while MI and MII equally 
contribute to trisomy 14 (Hall et al. 2007). Distinguishing parental origin can be of importance 
in cases of pregnancy loss or IVF treatment. It has been reported that men with female partners 
experiencing recurrent pregnancy loss have increased sperm aneuploidy compared with 
controls (Ramasamy et al. 2015). 
 
Table 1. Origin of trisomies. N – number of cases; MI – meiosis I; MII – meiosis II; PZM – post-zygotic mitotic. Adapted 
from Hassold et al. 2007. 
Trisomy 
 
N 
Maternal Paternal 
PZM (%) 
MI (%) MII (%) MI (%) MII (%) 
21 782 69.6 23.6 1.8 0.0 2.7 
18 150 33.3 58.7 0.0 0.0 8.0 
13 74 56.6 33.9 2.7 5.4 1.4 
 
1.1.5 Maternal age effect 
Studies of trisomies have demonstrated that the risk and incidence of aneuploidy is associated 
with increasing maternal age. The long time interval between meiotic arrest in the fetus and 
each ovulation cycle in the adult enable maternal age to affect aneuploidy incidence (Hassold 
& Hunt 2001). Theories of age-associated aneuploidies include recombination errors in early 
meiosis, deterioration of sister chromatid connection with age, a defective spindle assembly 
checkpoint, and maternal “genetic age” or telomere length (Chiang et al. 2012; Ghosh et al. 
2010). The impact of maternal age is substantial – 2% of all pregnancies among women under 
the age of 25 are trisomic, but the value approaches to 35% among women over 40 years of 
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age. There is no known influence of race, geography, or socio-economic status on maternal-
age-specific rates of trisomy (Hassold & Hunt 2001). 
Since the vast majority of aneuploidies, which originating from maternal errors, are in fact 
meiotic, therefore are age-dependent (Chiang et al. 2012). This does not apply to all cases, as 
non-disjunction is a complex mechanism influenced by factors and events both age-dependent 
and independent (Ghosh et al. 2010). The two-step mechanism provides an explanation 
combining these two. First, a fragile chiasmatic configuration is formed in the fetal oocyte, 
which is the age-independent step. Secondly, this event is followed by abnormal processing of 
the vulnerable bivalent at MI, that depends on maternal age (Muller et al. 2000). 
Maternal age is the most significant risk factor for non-disjunction resulting in DS (Sherman et 
al. 2006). Incidence of DS varies from about 1 in 1,200–1,600 to 1 in 20–30 in maternal age 
range 20–45 years, respectively (Cheslock et al. 2005). When evident relation between maternal 
origin of aneuploidy and advanced maternal age has been established, no conclusive connection 
has been demonstrated between paternal age and frequency of disomic sperm (Templado et al. 
2013). 
 
1.1.6 Trisomy 
The most common aneuploidies in humans are trisomies, which represent approximately 0.3% 
of all live births. Trisomies are characterized by the presence of one additional chromosome. 
Usually trisomies do not appear to be compatible with life, representing about 35% of 
spontaneous abortions (Hassold & Hunt 2001). Analyses show that regardless of the 
chromosome, most trisomies originate during oogenesis – therefore are maternal. This 
observation makes sense when considering that human oocytes can be arrested in prophase I 
for several decades. Usually errors of maternal MI are more common than errors of maternal 
MII and the proportion of cases of maternal origin increases with maternal age (Hassold & Hunt 
2001). However, chromosome-specific differences can occur as described in Table 1 (Hassold 
et al. 2007). 
Trisomy 16 is the most common trisomy, occurring more than 1% of all pregnancies (Hassold 
et al. 1995). However, this condition results in spontaneous miscarriage in the first trimester, 
only fetuses with mosaic form may survive (Langlois et al. 2006). The most common autosomal 
trisomies that survive to birth are (Parker et al. 2010): 
 Trisomy 21 (Down syndrome) – 1 in 700  
 Trisomy 18 (Edwards syndrome) – 1 in 4,000 
 Trisomy 13 (Patau syndrome) – 1 in 8,000 
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Individuals with DS are associated with physical growth delays, characteristic facial features, 
and mild to moderate intellectual disability, but patients routinely live to adulthood (Weijerman 
& de Winter 2010). In contrast, other autosomal trisomies have more severe effects and are 
rarely given birth alive. In fact, the only other autosomal trisomies, that are detected in any 
appreciable numbers, involve chromosomes 18 and 13, but newborns rarely survive beyond the 
first few months (Hassold & Hunt 2001). 
 
1.2 Current methods of prenatal diagnosis and screening 
Genetic prenatal diagnosis for fetal aneuploidies, such as trisomy 21, 18 and 13, has been an 
important part of prenatal medicine over 40 years now. Definitive prenatal diagnosis can be 
assessed only by sampling the fetal material, obtained through invasive testing, which is 
associated with a chance of fetal miscarriage (Chitayat et al. 2011). Therefore, to set a limit to 
invasive procedures, more convenient screening methods are used. 
There are several screening methods in use to assess the risk of chromosomal abnormalities, 
which vary in terms of gestation time, cost and accuracy. A list of different methods of prenatal 
diagnosis and screening are shown in Table 2. Once the high risk is identified, an invasive test, 
such as chorionic villus sampling, amniocentesis or cordocentesis, is performed to obtain the 
fetal genetic material for a definitive diagnosis. 
 
Table 2. Methods of prenatal diagnosis and screening. Sorted by invasiveness and time. Adopted and modified from 
Kotsopoulou et al. 2015. 
Invasiveness Method Time 
Non-invasive 
Preimplantation genetic diagnosis Before implantation 
Fetal cells in maternal blood 
First trimester 
Cell-free fetal DNA in maternal blood 
Ultrasound detection 
First or second trimester Fetal heartbeat 
Maternal serum screening 
Embryoscopy and fetoscopy After 20 weeks 
Invasive 
Chorionic villus sampling After 10 weeks 
Amniocentesis After 15 weeks 
Cordocentesis After 20 weeks 
 
One of the most widely used non-invasive screening method of fetal chromosomal pathologies 
is maternal serum screening with or without ultrasound scan. The combination of the two 
procedures is called the First Trimester Combined Test, which detects 78–90% of fetal 
aneuploidies and has a false positive rate around 5%. However, 95% of pregnant women, who 
result positive in the combined screening and follow an invasive procedure, are diagnosed with 
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no chromosomal pathology and therefore suffer an unnecessary stress and a risk of miscarriage 
(Russo & Blakemore 2014). Therefore, a more reliable and convenient method for prenatal 
diagnosis with a smaller risk of fetal loss or a more specific screening method with a lower rate 
of false positive results has long been searched for (Wright & Chitty 2009). 
 
1.3 Non-invasive cell-free DNA based screening 
Placenta has a two-way permeability – from fetus to mother and vice versa, having heavy traffic 
between the fetal and maternal sections (Lo et al. 1996). During pregnancy some cells of 
placenta undergo an apoptosis – a programmed cell death – which result in small fragments of 
DNA appearing in the maternal circulation. These fragments form cfDNA, part of which 
originates from fetus and is referred to as cffDNA (Alberry et al. 2007). 
For screening analysis, cfDNA is extracted from maternal plasma and used to assess the fetal 
genetic material (Lo et al. 1999). In addition to conventional screening methods, which can 
generally detect only the most common autosomal trisomies, NIPT has been used in 
determination of fetal sex, fetal rhesus D genotyping, prediction of gestational complications 
and even detection of single gene disorders (Ayse Kirbas, Korkut Daglar 2016). 
 
1.3.1 Cell-free fetal DNA 
The cffDNA was first described in 1997 and it consists of small DNA pieces of fetal origin, 
which circulate freely in the mother’s blood system until reaching to liver or kidneys for final 
utilization (Lo et al. 1997). These fragments are not within a cell, so they are unstable and have 
a short half-life up to 30 minutes (Lo et al. 1999). Studies of cfDNA have shown that the 
trophoblastic cells, which form the outer layer of a blastocyst and develop into a large part of 
the placenta, are the major source of cffDNA (Alberry et al. 2007). Only 3–13% of cfDNA in 
maternal circulation is fetal origin, the rest belongs to the mother (Wang et al. 2013). 
CffDNA can be detected in maternal blood as early as 7 weeks of gestation (Lo et al. 1998). At 
10 weeks the median cffDNA in total cfDNA is approximately 10% and the concentration 
increases 0.1% per week as the pregnancy advances (Wang et al. 2013). The percentage of 
cffDNA in total cfDNA, also known as fetal fraction, is similar to those in euploid pregnancies 
in trisomy 13 and 21, but noticeable depletion has been shown in trisomy 18. This decrease in 
fetal fraction has been linked to the smallness of placenta. Fetal fraction also decreases as 
maternal weight increases. Therefore, a cfDNA based aneuploidy screening may not be the best 
method for obese women (Palomaki et al. 2011). 
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1.3.2 Detection of aneuploidies 
The cffDNA from maternal blood has been used in detecting fetal aneuploidies such as 
trisomies and monosomies of autosomal and sex chromosomes (Fan et al. 2008; Samango-
Sprouse et al. 2013). A meta-analysis (Table 3) support that the cfDNA analysis of maternal 
blood can be used safely for fetal trisomy screening in singleton pregnancies. Trisomy 21 
screening with NIPT has been shown to be superior compared to the combination of 
conventional methods – mother’s age, ultrasound results and biochemical analysis of the 
maternal serum. However, the cfDNA screening test performance for trisomy 18 and 13 was 
not as sensitive compared to the trisomy 21 (Gil et al. 2015). 
 
Table 3. Summary of NIPT studies of common autosomal trisomies. Studies – number of studies; Cases – number of cases; 
DR – pooled weighted detection rate; CI – confidence interval; FPR – pooled weighted false positive rate. Adapted and 
modified from Gil et al. 2015. 
Trisomy Studies 
Cases 
DR (% (95% CI)) FPR (% (95% CI)) 
Trisomy Non-trisomy 
21 24 1,051 21,608 99.2 (98.5–99.6) 0.09 (0.05–0.14) 
18 21 389 21,306 96.3 (94.3–97.9) 0.13 (0.07–0.20) 
13 18 139 18,059 91.0 (85.0–95.6) 0.13 (0.05–0.26) 
 
There are several different approaches to detect fetal aneuploidy from cfDNA. These methods 
are commonly referred as NIPT. The first NGS based approaches employed genome-wide 
random sequencing, which enables to assess the proportion of each chromosome by counting 
the uniquely aligned sequences on each chromosome. If the proportion of a chromosome is 
increased, then it is considered that the fetus has trisomy (Fan et al. 2008). In scientific 
communities, these methods are called as the first-generation NIPT. 
The latter, next-generation NIPT approaches mostly use targeted sequencing, which focus on 
individual chromosomes or pre-defined regions in genome, requiring less cfDNA for analysis. 
Targeting involves the use of hybridization-based capture of the genomic regions of interest or 
the use of highly-multiplexed PCR to amplify SNPs followed by NGS (Liao et al. 2011; 
Zimmermann et al. 2012). Two of the next-generation NIPT approaches, that are widely used 
and commercially available in Estonia, are described in more detail in the next chapter (Ustav 
2015). 
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1.4 Computational methods for aneuploidy detection 
1.4.1 Next-generation Aneuploidy Test Using SNPs 
In 2012, Natera, Inc.1 in San Carlos, CA released Panorama™ Prenatal Test, which employs 
Next-generation Aneuploidy Test Using SNPs (NATUS) algorithm. The algorithm considers 
parental genotypes or, in the absence of a paternal sample, population allele frequencies and 
crossover frequency data2 to calculate the expected allele distributions for 19,488 SNPs and 
possible fetal genotypes based on recombination sites in the parent chromosomes. It compares 
predicted allelic distributions to measured allelic distributions by employing a Bayesian-based 
Maximum Likelihood approach to determine the relative likelihood of chromosomal copy 
number – monosomy, disomy or trisomy – hypothesis. The likelihoods of each sub-hypothesis, 
which are based on recombination sites, are summarized to find out the hypothesis with the 
maximum likelihood (Samango-Sprouse et al. 2013). 
NATUS takes into account a number of quality control indicators such as identifying sub-
optimal lab or sequencing results, estimating the amount of total starting DNA, determining the 
fetal fraction and calculating the extent of expected distributions to which the measured cfDNA 
data has to be fitted (Samango-Sprouse et al. 2013). 
 
1.4.2 Fetal Fraction Optimized Risk of Trisomy Evaluation 
In 2012, Ariosa Diagnostics, Inc.3 in San Jose, CA developed a novel assay – Digital Analysis 
of Selected Regions (DANSR). The assay enables targeted amplification of specific regions 
under investigation (Sparks et al. 2012). DANSR in combination with Fetal Fraction Optimized 
Risk of Trisomy Evaluation (FORTE) algorithm, which is designed to account for an 
individual’s age-related risks and the percentage of cffDNA in the sample to provide an 
individualized risk score for trisomy, are used in Harmony™ Prenatal Test (Stokowski et al. 
2015). 
DANSR approach is closely related to random whole genome sequencing, where the entire 
genome is evaluated using approximately 25 million raw reads per subject, which limits 
sequencing throughput to 4–6 samples per lane. The method includes an initial targeted 
amplification step in which 384 loci of each chromosome of interest are selectively amplified 
prior to NGS analysis. This targeted amplification results in an improvement in sequencing 
efficiency per target chromosome and compared to random genome-wide methods, DANSR 
uses 10 times less cfDNA and enables aneuploidy detection using approximately 1 million raw 
                                                 
1 http://www.natera.com/ 
2 https://www.ncbi.nlm.nih.gov/probe/docs/projhapmap/ 
3 http://www.ariosadx.com/ 
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reads per subject, which allows analysis of 96 subjects per sequencing lane. As with all 
quantitative methods, the approach is dependent on chromosomes having low amplification 
variability, which may limit its diagnostic accuracy for some chromosomes (Norwitz & Levy 
2013). 
Although quantitation of cfDNA for fetal aneuploidy screening to date has mostly relied upon 
NGS, this approach has been demonstrated to accurately quantify the targeted DANSR products 
for NIPT using DNA microarrays (Stokowski et al. 2015). Thus, DANSR has an advantage 
over NGS in terms of sequencing cost and throughput (Juneau et al. 2014). 
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2 STUDY 
2.1 Aim of the study 
The aim of the study was to evaluate the possibility to develop a computational data analysis 
method for a SNP-based NIPT to determine fetal trisomies and their parental origin. 
 
2.2 Methods 
2.2.1 Data simulation 
Three independent simulations were conducted to study the distribution of allelic ratios of SNPs 
in the cfDNA using R software4. As the cfDNA of a pregnant patient contains maternal and 
fetal genetic material, I started the simulation with the formation of chromosomes for each 
individual. Firstly, I created a pair of homologous chromosomes for either parent. For 
simplification each chromosome was generated as a vector of letters representing alleles of 
consecutive SNPs. Secondly, as homologous recombination takes place in meiosis, I switched 
half of the alleles between the copies of parental homologous chromosomes to simulate their 
offspring’s possible fetal genotype. Thirdly, I picked the recombinant chromosomes to form a 
pair of fetal chromosomes. In case of a normal fetus, two recombinant chromosomes were 
selected, one from each parent. In case of a trisomy, one recombinant chromosome originated 
from one parent and two from the other, depending on the parental origin of the trisomy. Lastly, 
having simulated the maternal and the fetal chromosomes, I mixed them together according to 
the theoretical allele frequencies (Table 4) in case of 1/10 fetal-to-maternal cell ratio (FMCR), 
which corresponds to the median fetal fraction (Ashoor et al. 2013). 
In case of normal fetus 9/10 of the observed chromosome is maternal and 1/10 fetal. In case of 
trisomy, fetal fraction of the observed chromosome is theoretically increased by one third, 
which shifts the overall proportion – 6/7 belongs to the mother and 1/7 to the fetus. 
 
Table 4. Theoretical allele frequencies and chromosomal fractions in cfDNA. The maternal and fetal allele frequencies and 
chromosomal fractions are calculated for three different fetal genotypes – normal, maternal and paternal trisomy. The 
calculations are carried out in 1/10 FMCR. 
Fetal genotype 
Maternal Fetal 
Allele Chromosomal 
fraction 
Allele Chromosomal 
fraction N Frequency N Frequency 
Normal 
2 
9/20 9/10 2 1/20 1/10 
Maternal trisomy 
9/21 6/7 3 1/21 1/7 
Paternal trisomy 
                                                 
4 https://www.r-project.org/ 
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As a result, 440 000 000 reads were generated per simulation to cover 440 000 virtual SNPs, 
which makes an average of 1 000 reads per SNP. 
 
2.2.2 Allelic distribution and informative SNPs 
The simulations incorporate only highly polymorphic SNPs where minor allele frequency is 
equal to major allele frequency. If both alleles of a SNP are present in cfDNA, regardless 
whether they derive from the mother or the fetus, the SNP is defined as an informative SNP 
(Figure 2). In case of equally balanced alleles I expect that 1/2 of SNPs are heterozygous in 
mother and fetus. As allelic ratio can be calculated even if only one of the individuals is 
heterozygous, I would expect that 3/4 of all SNPs are heterozygous in case of normal fetus. 
In case of maternally inherited trisomy, the expected proportion of heterozygous SNPs remains 
the same as in case of normal fetus – 3/4. In case of paternally inherited trisomy, the proportion 
of informative SNPs is higher as fetal alleles also express paternal heterozygosity. The opposite 
event, SNP being homozygous, occurs only when the mother and father are both homozygous 
and the alleles match – 1/8 of total SNPs. To get the probability of a SNP being informative in 
case of paternal trisomy, I subtract 1/8 from all possibilities which gives us 7/8. 
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Figure 2. Chromosomal schemes of allelic distribution. (A) Normal fetus. (B) Maternal trisomy. (C) Paternal trisomy. Loci 
surrounded by red rectangle represent informative SNPs. 
 
2.2.3 Allelic ratio 
Using previously simulated data, the number of reads containing major and minor alleles were 
counted in each locus. Then, considering only the informative SNPs where both alleles were 
present, I calculated allelic ratios as follows: 
 
𝑎𝑙𝑙𝑒𝑙𝑖𝑐 𝑟𝑎𝑡𝑖𝑜𝑖 =
𝑚𝑎𝑗𝑜𝑟 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑖
𝑚𝑖𝑛𝑜𝑟 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑖
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where i represents the ith informative SNP for studied sample. 
For detection of fetal trisomy, I have to compared the measured allelic ratios with the expected 
allelic ratios specific to each possible combination of maternal and fetal genotype (Table 5). 
Before calculating the expected allelic ratios, FMCR must be known in advanced. The 
calculation of FMCR is described in more detail in the next chapter. 
 
Table 5. Allelic ratio dependency on maternal and fetal zygosity and genotype. Formulas of expected allelic ratios by 
maternal and fetal zygosity in case of different fetal genotypes – normal, maternal and paternal trisomy. MA – maternal allele; 
FA – fetal allele; * – theoretically impossible. 
Fetal 
genotype 
Maternal 
zygosity 
Fetal 
zygosity 
Major 
allele 
Minor 
allele 
Allelic 
ratio 
Normal 
Homozygous 
Homozygous 2𝑀𝐴 + 2𝐹𝐴 - - 
Heterozygous 2𝑀𝐴 + 𝐹𝐴 𝐹𝐴 
2𝑀𝐴 + 𝐹𝐴
𝐹𝐴
 
Maternal trisomy 
Homozygous 2𝑀𝐴 + 3𝐹𝐴 - - 
Heterozygous 2𝑀𝐴 + 2𝐹𝐴 𝐹𝐴 
2𝑀𝐴 + 2𝐹𝐴
𝐹𝐴
 
Paternal trisomy 
Homozygous 2𝑀𝐴 + 3𝐹𝐴 - - 
Heterozygous 2𝑀𝐴 + 2𝐹𝐴 𝐹𝐴 
2𝑀𝐴 + 2𝐹𝐴
𝐹𝐴
 
Normal 
Heterozygous 
Homozygous 𝑀𝐴 + 2𝐹𝐴 𝑀𝐴 
𝑀𝐴 + 2𝐹𝐴
𝑀𝐴
 
Heterozygous 𝑀𝐴 + 𝐹𝐴 𝑀𝐴 + 𝐹𝐴 
𝑀𝐴 + 𝐹𝐴
𝑀𝐴 + 𝐹𝐴
 
Maternal trisomy 
Homozygous* 𝑀𝐴 + 3𝐹𝐴 𝑀𝐴 
𝑀𝐴 + 3𝐹𝐴
𝑀𝐴
 
Heterozygous 𝑀𝐴 + 2𝐹𝐴 𝑀𝐴 + 𝐹𝐴 
𝑀𝐴 + 2𝐹𝐴
𝑀𝐴 + 𝐹𝐴
 
Paternal trisomy 
Homozygous 𝑀𝐴 + 3𝐹𝐴 𝑀𝐴 
𝑀𝐴 + 3𝐹𝐴
𝑀𝐴
 
Heterozygous 𝑀𝐴 + 2𝐹𝐴 𝑀𝐴 + 𝐹𝐴 
𝑀𝐴 + 2𝐹𝐴
𝑀𝐴 + 𝐹𝐴
 
 
2.2.4 Fetal-to-maternal cell ratio 
Allele frequencies of a reference chromosome, that will unlikely be aneuploidy, were used to 
estimate the FMCR. For that I counted allele frequencies of the simulation of normal fetus and 
filtered the SNPs where mother is homozygous (allelic ratio >2.5). In this subset, the major 
allele frequency includes three sets of reads – two equal parts from the mother and one smaller 
part from the fetus. The minor allele frequency includes only one set of reads from the fetus 
that is equal with the fetal part of the major allele frequency (Table 5). Based on the previous 
theory, I extracted the estimated maternal and fetal allele frequencies from the major and the 
minor allele frequencies and calculate the estimated FMCR as follows: 
23 
 
 
𝐹𝑀𝐶𝑅 =
2 ∗ ∑ (𝑚𝑖𝑛𝑜𝑟 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑖)
𝑛
𝑖=1
∑ (𝑚𝑖𝑛𝑜𝑟 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑖 + 𝑚𝑎𝑗𝑜𝑟 𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑖)
𝑛
𝑖=1
 
 
where i represents the observed locus and n represents the total number of observed SNPs. 
Using the estimated FMCR (~0.100), which was almost ideally confirmed by the FMCR set in 
simulations (0.1), I calculated the expected allelic ratios in case of every possible outcome. The 
expected allelic ratios in case of different FMCR are visualized on Figure 3. 
 
 
Figure 3. Relationship between allelic ratios of different fetal genotypes and FMCR. Upper panel represents maternal 
heterozygosity and lower panel represents maternal homozygosity. The dashed line represents fetal homozygosity and the solid 
line represents fetal heterozygosity. 
 
2.2.5 Analytical approach 
All calculations were performed in R software (version 3.3.0). For t-test based approach I used 
Welch’s t-test from “The R Stats Packages” (stats version 3.3.0) with default parameters which 
in case of two input vectors applies two-sided unpaired t-test expecting unequal variance and 
significance level of 0.05. 
For HMM I used “Dependent Mixture Models – Hidden Markov Models of GLMs and Other 
Distributions in S4” (depmixS4 version 1.3-3) package. I created a 4-state HMM to separate 
allelic ratios by the combination of fetal zygosity and genotype – two hidden states for normal 
and two for trisomy (Figure 4). The HMM is designed for maternal heterozygosity only (Figure 
3). The expected allelic ratios (Table 5) according to the estimated FMCR were used as the 
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means of observations associated with the states and the standard deviations of observations 
were fix to 0.05 in order to avoid excessive overlap. The transition probabilities of hidden states 
were symmetrical – 0.49 between two normal states or two trisomies and 0.01 between normal 
and trisomy. The initial hidden state probabilities were chosen according to the live birth 
prevalence of DS – 1 in 700 (Parker et al. 2010). Finally, Viterbi algorithm was used to find the 
most likely sequence of hidden states. 
 
 
Figure 4. HMM. The circles represent hidden states and the ovals represent the distribution of expected allelic ratios. The 
black arrows with probabilities represent the transitions between the hidden states. 
 
2.3 Results 
Simulated data was generated per each fetal genotype to call informative SNPs (Table 6). 
Comparing the results of simulations with the theoretical calculations of informative SNPs 
described in chapter 2.2.2, we see that the proportion of informative SNPs out of the total 
number of SNPs differs very little from what is expected – approximately 1% at most. This 
assures that the simulations are conducted in accordance with the theory. 
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Table 6. Summary of simulated SNPs. Includes simulations of three fetal genotypes – normal, maternal and paternal trisomy. 
Simulated fetal 
genotype 
Number 
of SNPs 
in total 
Informative SNPs 
Maternal zygosity 
Total 
Homozygous Heterozygous 
N % N % N % 
Normal 
440,000 
110,115 25.03 219,458 49.88 329,573 74.90 
Maternal trisomy 110,071 25.02 221,355 50.31 331,426 75.32 
Paternal trisomy 164,975 37.49 219,882 49.97 384,857 87.47 
 
Comparing the three simulations, I distinguish that the distributions of allelic ratios of 
informative SNPs have different patterns depending on the fetal genotype (Figure 5). Allelic 
ratio is mainly influenced by the maternal zygosity and less by the fetal zygosity, as most of the 
cfDNA in blood belongs to the mother (Wang et al. 2013). On that basis, allelic ratio can be 
divided into two distinct groups by maternal zygosity. In case of 1/10 FMCR, the allelic ratio 
of a SNP where mother is heterozygous is close to 1 (Figure 8). If the mother is homozygous 
and the heterozygosity derives from the paternally inherited chromosome(s) of the fetus, then 
the allelic ratio is nearly 10 times higher depending on the parental origin of the fetal trisomy 
(Figure 6). 
 
 
Figure 5. Distribution of allelic ratios. Simulated 440 000 SNPs per genotype and 1 000 reads per SNP in average. The SNPs 
of normal fetus, fetus with maternal trisomy and fetus with paternal trisomy were converted into respectively 329 573, 331 426 
and 384 857 allelic ratios. Allelic ratios close to 1 represent maternal heterozygosity and allelic ratios close to 9.5, 19 and 20 
represent maternal homozygosity. The simulations are conducted in 1/10 FMCR. 
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2.3.1 Detection of trisomy with t-test 
The calculations based on the expected allelic ratios (Table 5) show that in case of homozygous 
mother and 1/10 FMCR (Figure 6) there is a ~5% difference between allelic ratio of normal 
fetus (μ = 19) and fetus with maternally inherited trisomy (μ = 20). The difference increases 
slowly with the growth of the FMCR (Figure 3). Paternally inherited trisomy, however, has two 
different scenarios. If only one paternally inherited fetal allele is different from the maternal 
alleles then the distribution of allelic ratio is identical to maternally inherited trisomy, if both 
alleles are different then the allelic ratio is 50% smaller (μ = 9.5) than in case of a normal fetus. 
 
 
Figure 6. Distribution of allelic ratio typical to maternal homozygosity. Allelic ratio is over 2.5 in ~33% of all informative 
SNPs of fetus with normal genotype, ~33% of fetus with maternal trisomy and ~43% of fetus with paternal trisomy. 
 
Based on the previously described differences of allelic ratios, I wanted to know how many 
SNPs are necessary for the detection of trisomy with two-sided Welch’s t-test assuming 
heteroscedasticity. Using the simulated data, I compared the allelic ratios of normal fetus with 
the allelic ratios of fetus with maternally inherited trisomy by conducting a series of two-sample 
t-tests with variable number of informative SNPs. The statistical testing involved allelic ratios 
of informative SNPs typical to maternal homozygosity (Figure 6). As a result, I found that on 
average, at least 70 informative SNPs are necessary to detect full maternal trisomy (Figure 7). 
Considering the fact that approximately 1/4 of all SNPs are informative in case of homozygous 
mother and normal fetus or fetus with maternally inherited trisomy in our simulation (Table 6), 
then in total about 300 highly polymorphic SNPs are required to detect full maternal trisomy. 
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The allelic ratios of paternally inherited trisomy differentiate even more from the allelic ratios 
of normal fetus than the allelic ratios of maternally inherited trisomy, but as the distribution of 
the allelic ratios of paternally inherited trisomy is a bimodal distribution with two separate 
peaks, then the assumption of normal distirbution is not met and using t-test is not optimal. 
 
 
Figure 7. Relationship between number of informative SNPs and t-test p-value. Each point represents the median of p-
values of 10 000 conducted t-tests between equal number of informative SNPs of allelic ratios of normal fetus and fetus with 
maternal trisomy. The blue line represents the local polynomial regression fitting (loess) curve and the red line represents the 
selected significance cut-off (α = 0.05). 
 
2.3.2 Detection of trisomy with hidden Markov model 
The allelic ratios of informative SNPs in cfDNA are distributed between four distinct intervals 
in case of maternal heterozygosity (Figure 8). The four groups are formed by the combination 
of fetal zygosity and genotype as follows with expected allelic ratio: 
 Heterozygous fetus with normal genotype (μ = 1) 
 Heterozygous fetus with maternal or paternal trisomy (μ = 1.1) 
 Homozygous fetus with normal genotype (μ = ~1.2) 
 Homozygous fetus with paternal trisomy (μ = ~1.3) 
The difference between the expected allelic ratios in adjacent groups are close to ~10% and 
increase with the increase of FMCR (Figure 3). 
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Figure 8. Distribution of allelic ratio typical to maternal heterozygosity. Allelic ratio is less than 2.5 in ~67% of all 
informative SNPs of fetus with normal genotype, ~67% of fetus with maternal trisomy and ~57% of fetus with paternal trisomy. 
 
I used allelic ratios of simulated fetal genotypes (Figure 8) to estimate fetal disomy or trisomy 
by HMM. Close to 220 000 informative SNPs per simulation were divided between previously 
described states (Figure 4). The results reveal the true underlying genotypes behind the 
simulated fetal genotypes in all three occations. In total, 63.37% of informative SNPs of normal 
fetal genotype, 83.99% of maternal trisomy and 96.48% of paternal trisomy are classified 
correctly (Table 7). As FMCR increases, the differences between the allelic ratios also increase 
which should ease the detection of underlying fetal genotype of SNPs (Figure 3). 
 
Table 7. The estimated fetal genotype by HMM. Includes simulations of three fetal genotypes – normal, maternal and 
paternal trisomy. 
Simulated 
fetal genotype 
Number 
of 
SNPs 
Estimated fetal genotype (%) 
Normal 
Trisomy 
Maternal/Paternal Paternal Total 
Normal 219,458 63.37 26.18 10.44 36.63 
Maternal trisomy 221,355 11.58 83.99 4.43 88.42 
Paternal trisomy 219,882 3.52 69.95 26.53 96.48 
 
To illustrate the performance of the HMM analysis in patient-specific cases, I took the first 500 
sequential informative SNPs and performed an analysis using the previously defined HMM. 
The results were similar to the previously obtained outcomes, confirming that the HMM 
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analysis with selected parameters performs as expected in case of realistic number of SNPs 
(Figure 9). 
 
 
Figure 9. Estimated fetal genotypes of sequential SNPs by HMM. Estimation incorporated allelic ratios of 500 sequential 
SNPs per fetal genotype. Simulation of maternal trisomy (upper panel) resulted in ~17% (84) of normal genotype (green) and 
~83% (416) of trisomy (red), simulation of normal fetus (center panel) resulted in 67% (335) of normal and 33% (165) of 
trisomy and simulation of paternal trisomy (lower panel) resulted in ~7% (34) of normal and ~93% (466) of trisomy. 
 
2.4 Discussion 
There are several NIPT methods available for prenatal screening of fetal aneuploidy. Compared 
with the first-generation NIPT algorithms, the SNP-based analytical approach has several 
advantages – it does not require sequencing of the whole genome nor does it require prior 
knowledge of parental genotypes to detect fetal trisomy (Norwitz & Levy 2013). Targeting only 
pre-defined regions, as methods described in chapter 1.4, enables to sequence multiple patients 
in parallel, which keeps the sequencing cost low and makes it a promising alternative to current 
methods. In addition, the described method can discover the parental origin of fetal trisomy, 
which simplifies the identification of underlying problem and allows to focus on finding a 
patient-specific solution. 
There are also a few shortcomings. Firstly, the approach has only been tested on simulated data. 
In case of real data, greater variation in allele frequencies may be expected, which may fuse the 
difference between the allelic ratios of normal fetus and fetus with trisomy, or even encounter 
unexpected distribution of allelic ratios, which are difficult to interpret. Secondly, it is designed 
for detection of common autosomal trisomies which form a major proportion of aneuploidies. 
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Competing methods can also detect other chromosomal abnormalities like monosomies, sex 
chromosome disorders, microdeletions and microduplications (Samango-Sprouse et al. 2013). 
Some NIPT studies even claim to be able to detect fetal aneuploidies in twin pregnancies 
(Huang et al. 2014). 
As this method is still in active development phase, there are several ideas how to improve the 
accuracy. At first, HMM parameters can be optimized according to the real data. Also, it is 
possible to use even chromosome-specific HMM models, which could take into account 
maternal age, prevalence of the disease in general or specific populations and other traits which 
are correlated or have been associated with chromosomal aneuploidies. 
Finding a sufficient quantity of highly polymorphic SNPs that are evenly distributed over the 
whole studied chromosome is crucial for this approach. Approximately 3/4 of highly 
polymorphic SNPs are informative by random distribution of parental alleles and therefore 
useful for the analysis (Table 6). Lower amount of SNPs could lead to unreliable results due to 
the greater uncertainty. Possibly, this could be solved by increasing read depth of coverage in 
sequencing or by increasing the number of analyzed SNPs. 
At the moment, the 4-state HMM was adjusted for maternal heterozygosity and used 
approximately 2/3 of the informative SNPs, which accounts for approximately 1/2 of all SNPs 
(Table 6). Adding three extra states to the HMM, which are typical to maternal homozygosity, 
would incorporate all the informative SNPs. The shortage of the 7-state model is that the 
difference between the allelic ratios of these extra states is smaller and it would be harder to 
differentiate fetal genotypes. Alternatively, it would be possible to use higher amount of SNPs 
and the 3-state model. 
Viterbi algorithm is used by default to estimate the most likely fetal genotype underlying each 
SNP. Although being optimal for obtaining the maximum probability, Viterbi algorithm does 
not minimize the number of expected classification errors. Relatively fewer expected errors 
could result from using “pointwise maximal a posterior” (PMAP) estimator which has its own 
disadvantages. Having a false negative result is less preferable than obtaining a false positive 
result as such screening result is confirmed or disconfirmed later by a diagnostic method. 
Unfortunately, PMAP may have very low posterior probability. A solution could be a hybrid-
estimator that combines the properties of previously described estimators (Lember & 
Koloydenko 2014). Further testing has to be carried out in this matter. 
One way to improve the accuracy of such analytical approach may be to use a combination of 
different statistical tests. Combining the 3-state HMM, which fits for allelic ratios where mother 
is heterozygous, and the t-test, which is suitable for allelic ratios where mother is homozygous, 
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takes an advantage of a larger number of SNPs than either test separately. The combination of 
the two tests may provide a more reliable result in case of fewer informative SNPs. 
Further, we plan to add new features to the current analytical approach. First, real data is needed. 
Next task is to expand the theoretical calculations of allele frequencies for monosomy and sex 
chromosome aneuploidies. If characteristics of allelic ratios that are unique for a certain 
condition can be described, similar concept may be applied. 
The HMM is based on Markov chain, which in the model means that the next SNP depends 
only on the current SNP and not on the SNPs that preceded it. Having pre-defined SNPs, we 
can easily locate them on a chromosome and find the distance between SNPs. If two sequential 
SNPs are situated closer together, they are more likely to be in the same state, whether it is a 
normal or an aneuploidy. Relying on the previous statement, the plan is to detect partial 
chromosomal abnormalities where only a certain part of the chromosome is duplicated or 
deleted. This can be done by splitting the chromosome virtually into consecutive bins, followed 
by bin by bin analysis and chromosomal state determination. 
As the approach described here is based on allelic ratios of observed parental alleles, then it 
should be also suitable for detection of UPD. In case of isodisomy, in which a single pair of 
duplicated chromosomes are inherited, we expect to see high level of fetal homozygosity in 
observed chromosome. 
In conclusion, analysis of only hundreds of highly polymorphic SNPs over risk- and reference 
chromosomes has a high potential to make NIPT laboratory analysis and computational 
methods much more cost- and resource effective. It enables to reduce the price of NIPT, making 
it available for all pregnant women in an early phase of pregnancy. As my study was conducted 
on simulated data, which provided sufficient results for distinguishing normal fetus and fetus 
with maternally or paternally inherited trisomy, highly quantitative genotyping results from real 
trisomy cases are needed to prove the concept described in this study. 
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SUMMARY 
Using NIPT to detect fetal chromosomal aneuploidies from mother’s blood sample has proven 
to be an accurate and reliable method. In this study, the only aneuploidy we focused on was 
trisomy. Using three sets of simulated data, which consisted of a combination of maternal and 
one of the fetal genotypes – normal, maternally and paternally inherited trisomy. Comparing 
the simulated allelic ratios of informative SNP with the expected allelic ratios revealed that the 
detection of fetal trisomy is theoretically possible. 
However, NIPT is considered as screening method, which means that for diagnosis, patient 
needs to undergo an invasive procedure to be fully confirmed. As the accuracy of NIPT is 
exceptional, decreasing number of pregnant women need to be mistakenly examined by 
invasive techniques, which pose ~1% risk of miscarriage. Also, accurate prenatal screening 
makes difficult decision in case of possible chromosomal pathology easier for parents. 
The second aim of the study was to determine a parental origin if the trisomy is confirmed. 
Using the HMM, we managed to estimate parental origin even though the allelic ratios of 
maternally and paternally inherited trisomies overlap in some cases. Knowing the parental 
origin may be important in case of infertility problems by narrowing down the possible causes, 
which helps physicians to focus on finding a patient-specific solution. 
In conclusion, the highly quantitative SNP-based approach, that is under development by our 
research group, has theoretically a good potential to meet the need of being a cost-effective 
alternative to current NIPT method. However, further testing has to be carried out with the real 
data. 
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KOKKUVÕTE 
NIPT on tõestanud end kui täpse ja usaldusväärse meetodina loote kromosomaalsete 
aneuploidiate detekteerimiseks. Uurimuses keskendusime vaid trisoomia tuvastamisele, 
kasutades kolme simuleeritud andmestikku, mis koosnesid ema ja ühe võimaliku loote 
genotüübi – normaalne, ema- ja isapoolne trisoomia – andmetest. Simuleeritud informatiivsete 
SNP-de alleelsete suhete võrdlemine oodatud alleelsete suhetega näitas, et loote trisoomia 
detekteerimine on teoreetiliselt võimalik. 
NIPT puhul on tegemist skriininmeetodiga, mis tähendab, et positiivse testitulemuse 
kinnitamiseks peab patsient läbima invasiivse diagnostilise protseduuri. Kuna NIPT on 
erakordselt täpne, siis järjest vähem rasedaid vajab ekslikult invasiivset kontrolli, millega 
kaasneb ~1% nurisünnituse risk. Lisaks lihtsustab täpne prenataalne skriining kõrge 
riskihinnangu korral vanematel langetada raskeid otsuseid. 
Töö teine eesmärk oli trisoomia vanemliku päritolu määramine. HMM analüüsi rakendades 
õnnestus meil hinnata trisoomia vanemlikku päritolu hoolimata sellest, et ema- ja isapoolse 
päritoluga trisoomiate alleelisuhetes on osaline kattuvus. Trisoomia vanemiliku päritolu 
teadmine võib osutuda oluliseks viljakusprobleemide lahendamisel, vähendades võimalike 
põhjuste koguhulka, mis võimaldab arstidel keskenduda patsiendispetsiifiliste probleemide 
lahendamisele. 
Kokkuvõtteks on antud SNP-põhisel lähenemisel, mida arendatakse hetkel aktiivselt meie grupi 
poolt, hea teoreetiline eeldus olla hinnasõbralikum alternatiiv praegustele NIPT meetoditele. 
Siiski on lõpliku kindluse saavutamiseks vaja analüüsi kontrollida reaalsete andmetega. 
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